Share
Mark McLellan
Epiminder Limited, a pioneering medical device company advancing breakthrough epilepsy monitoring solutions, has appointed Mark McLellan as its new Chief Financial Officer.
This leadership addition comes at a pivotal time for Epiminder, following the recent FDA authorization of its Minder® implantable continuous EEG monitoring (iCEM®) system - a significant milestone in the company’s mission to transform long-term epilepsy monitoring and management.
Mark McLellan brings a wealth of experience in healthcare finance, technology strategy, and capital markets to his new role. His background includes senior leadership positions at Beamtree Holdings Ltd, where he contributed to the commercialization of medical data services, and at rhipe (now Crayon), where he gained extensive expertise in supporting high-growth technology businesses. His strategic insight into scaling innovative companies will be instrumental as Epiminder prepares for its next phase of expansion.
Earlier in his career, McLellan held key roles in strategic planning and financial advisory at PwC, Ernst & Young, and the Royal Bank of Scotland. During this time, he supported numerous organizations through IPOs, private capital raisings, acquisitions, and divestments - experience that will be critical in guiding Epiminder’s financial strategy, investor engagement, and long-term growth.
In his new role as CFO, McLellan will oversee financial operations, help shape corporate strategy, and support the commercial acceleration of Epiminder’s groundbreaking iCEM® technology. His appointment strengthens the company’s leadership team and reinforces Epiminder’s commitment to delivering innovative, high-impact solutions for people living with epilepsy.
Related posts
